Tong Stephen, Kaitu'u-Lino Tu'uhevaha J, Onda Kenji, Beard Sally, Hastie Roxanne, Binder Natalie K, Cluver Cathy, Tuohey Laura, Whitehead Clare, Brownfoot Fiona, De Silva Manarangi, Hannan Natalie J
From the Translational Obstetrics Group, the Department of Obstetrics and Gynaecology, Mercy Hospital for Women, University of Melbourne, Heidelberg, Victoria, Australia (S.T., T.J.K.-L., K.O., S.B., R.H., N.K.B., C.C., L.T., C.W., F.B., M.D.S., N.J.H.); Department of Clinical Pharmacology, Tokyo University of Pharmacy and Life Sciences, School of Pharmacy, Tokyo, Japan (K.O.); and Department of Obstetrics and Gynaecology, Tygerberg Hospital, Stellenbosch University, Stellenbosch, South Africa (C.C.).
Hypertension. 2015 Nov;66(5):1073-81. doi: 10.1161/HYPERTENSIONAHA.115.05847. Epub 2015 Aug 31.
Elevated placental release of the antiangiogenic factors, soluble fms-like tyrosine kinase-1 (sFlt-1) and soluble endoglin (sENG), is central to the pathophysiology of preeclampsia. It is widely accepted that heme oxygenase-1 (HO-1) is decreased in preeclamptic placenta and negatively regulates sFlt-1 and sENG production. We set out to verify these contentions. There was no difference in HO-1 mRNA or protein levels in preterm preeclamptic placentas (n=17) compared with gestationally matched controls (n=27). In silico analysis of microarray studies did not identify decreased placental HO-1 expression in preeclamptic placenta. Silencing HO-1 in primary trophoblasts did not affect sFlt-1 protein secretion after 24 or 48 hours. Silencing nuclear factor (erythroid-derived 2)-like 2 (transcription factor that upregulates HO-1) in trophoblasts also did not affect sFlt-1 secretion. Administering tin protoporphyrin IX dichloride (HO-1 inhibitor) or cobalt protoporphyrin (HO-1 inducer) into placental explants did not affect sFlt-1 or sENG secretion. Silencing HO-1 in 2 types of primary endothelial cells (human umbilical vein endothelial and uterine microvascular endothelial cells) significantly increased sFlt-1 secretion but not sENG secretion. However, HO-1 silencing selectively increased mRNA expression of sFlt-1 i13 (generically expressed sFlt-1 variant) but not of sFlt-1 e15a (sFlt-1 variant mainly expressed in placenta). Furthermore, adding tin protoporphyrin IX dichloride decreased sFlt-1, whereas adding HO-1 inducers (cobalt protoporphyrin, dimethyl fumarate, and rosiglitazone) either had no effect or increased sFlt-1 or sENG secretion (these trends are opposite to what is expected). We conclude that HO-1 expression is not decreased in preeclamptic placenta and HO-1 does not negatively regulate placental sFlt-1 and sENG secretion in placental or endothelial cells.
抗血管生成因子可溶性fms样酪氨酸激酶-1(sFlt-1)和可溶性内皮糖蛋白(sENG)的胎盘释放增加是子痫前期病理生理学的核心。血红素加氧酶-1(HO-1)在子痫前期胎盘中减少并负向调节sFlt-1和sENG的产生,这一观点已被广泛接受。我们着手验证这些观点。与孕周匹配的对照组(n = 27)相比,早产子痫前期胎盘(n = 17)中HO-1 mRNA或蛋白水平没有差异。对微阵列研究的计算机分析未发现子痫前期胎盘中胎盘HO-1表达降低。在原代滋养细胞中沉默HO-1在24或48小时后不影响sFlt-1蛋白分泌。在滋养细胞中沉默核因子(红系衍生2)样2(上调HO-1的转录因子)也不影响sFlt-1分泌。向胎盘外植体中给予二氯化锡原卟啉IX(HO-1抑制剂)或钴原卟啉(HO-1诱导剂)不影响sFlt-1或sENG分泌。在两种原代内皮细胞(人脐静脉内皮细胞和子宫微血管内皮细胞)中沉默HO-1显著增加sFlt-1分泌,但不增加sENG分泌。然而,HO-1沉默选择性增加sFlt-1 i13(普遍表达的sFlt-1变体)的mRNA表达,但不增加sFlt-1 e15a(主要在胎盘中表达的sFlt-1变体)的mRNA表达。此外,添加二氯化锡原卟啉IX降低sFlt-1,而添加HO-1诱导剂(钴原卟啉、富马酸二甲酯和罗格列酮)要么没有影响,要么增加sFlt-1或sENG分泌(这些趋势与预期相反)。我们得出结论,子痫前期胎盘中HO-1表达未降低,并且HO-1在胎盘或内皮细胞中不会负向调节胎盘sFlt-1和sENG的分泌。